ATC Group: L03AA14 Lipegfilgrastim

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AA14 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AA Colony stimulating factors
5 L03AA14

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 0.3 mg

Active ingredients in L03AA14

Active Ingredient Description
Lipegfilgrastim

Lipegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Lipegfilgrastim binds to human the G-CSF receptor like filgrastim and pegfilgrastim. Human G-CSF is a glycoprotein that regulates the production and release of functional neutrophils from the bone marrow.

Related product monographs

Title Information Source Document Type  
LONQUEX Solution for injection in pre-filled syringe European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Austria (AT)

Brazil (BR)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.